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A B S T R A C T
Objectives: New adjuvant treatments are being developed for patients with resected non-small cell lung cancer
(NSCLC). Due to scarcity of real-world data available for treatment costs and resource utilization, health tech-
nology and cost-eﬀectiveness assessments can be limited. We estimated the burden and cost-of-illness associated
with completely resected stage IB-IIIA NSCLC in France, Germany and the United Kingdom (UK).
Materials and methods: Eligible patients were aged ≥18 years with completely resected stage IB-IIIA NSCLC
between August 2009 and July 2012. Patients (living or deceased) were enrolled at clinical sites by a systematic
sampling method. Data were obtained from medical records and patient surveys. Direct, indirect and patient out-
of-pocket expenses were estimated by multiplying resource use by country-speciﬁc unit costs. National annual
costs were estimated based on disease prevalence data available from published sources.
Results: 39 centers provided data from 831 patients of whom patient surveys were evaluable in 306 patients.
Median follow-up was 26 months. The mean total direct costs per patient during follow-up were: €19,057
(France), €14,185 (Germany), and €8377 (UK). The largest cost drivers were associated with therapies received
(€12,375 France; €3694 UK), and hospitalization/emergency costs (€7706 Germany). Monthly direct costs per
patient were the highest during the distant metastasis/terminal illness phase in France (€15,562) and Germany
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(€6047) and during the adjuvant treatment period in the UK (€2790). Estimated mean total indirect costs per
patient were: €696 (France), €2476 (Germany), and €1414 (UK). Estimates for the annual national direct cost
were €478.4 million (France), €574.6 million (Germany) and €325.8 million (UK).
Conclusion: To our knowledge, this is the ﬁrst comprehensive study describing the burden of illness for patients
with completely resected stage IB-IIIA NSCLC. The economic burden was substantial in all three countries.
Treatment of NSCLC is associated with large annual national costs, mainly incurred during disease progression.
1. Introduction
Lung cancer is the most commonly diagnosed cancer and frequent
cause of cancer death worldwide [1]. The majority of lung cancers are
diagnosed as non-small cell lung cancer (NSCLC) [2]. Complete surgical
resection is the recommended therapy in all guidelines, and is used to
treat NSCLC Stages (I–II) and speciﬁc cases of Stage IIIA disease [3–5].
Cisplatin-based adjuvant chemotherapy recommended for patients with
Stage II-IIIA disease provides a small (5.8%) beneﬁt in the 5-year rate of
disease-free survival, although the associated toxicity is substantial
[6,7]. With standard treatment, patients with resected NSCLC have a 5-
year overall survival of 58–73% for Stage I, 36–46% for Stage II and
24% for Stage III [3,4].
There is a need for improved NSCLC treatments with higher eﬃcacy
and reduced toxicity compared to platinum-based regimens. New
treatments for advanced NSCLC, such as targeted therapies, anti-
angiogenic agents and immune checkpoint inhibitors, are currently
being investigated in early stage NSCLC [8,9]. However, cost and af-
fordability have been identiﬁed as major factors contributing to in-
equitable access to NSCLC anti-cancer drugs in European countries
[10]. In many countries, decisions concerning drug access are made by
health technology assessment agencies and reimbursement authorities.
Data describing treatment patterns, outcomes in routine clinical prac-
tice, and an understanding of resource use and costs, which are not
collected during clinical trials, are necessary to the quality of the de-
cisions made by these agencies. To our knowledge, there are no com-
prehensive burden-of-illness data for patients with completely resected
stage IB-IIIA NSCLC.
We report a retrospective, observational burden-of-illness study in
France, Germany and the United Kingdom (UK) among 831 patients
with completely resected stage IB-IIIA NSCLC (LuCaBIS: a burden-of-
illness study in patients with stage IB-IIIA Non-Small Cell Lung Cancer
in France, Germany, and the United Kingdom). Using medical charts
and patient surveys, we identiﬁed low use of adjuvant therapy in pa-
tients with Stage IB disease (15.1%). Higher treatment rates were seen
in more advanced disease stages (Stage IIA, 52.0%; Stage IIB, 58.2%;
Stage IIIA, 71.4%), for which available evidence more consistently
shows a survival beneﬁt.
A similar pattern of adjuvant treatment use was observed in each
country in terms of stage, although for each stage and overall, adjuvant
chemotherapy was administered most frequently in France (61.8% of
patients), intermediately in Germany (51.9%), and was used the least in
the UK (33.4%). 40% of patients had disease recurrence or died during
the study follow-up period (median follow-up of 26 months). Here we
report the resource utilization and monetary costs associated with pa-
tients with completely resected stage IB-IIIA NSCLC from the same
study.
The clinical aspects of this study are reported in a back-to-back
manuscript in this issue.
2. Materials and methods
The study (ClinicalTrials.gov identiﬁer: NCT01772225) was con-
ducted in 39 specialist cancer centers, teaching hospitals and tertiary
referral centers in France (14 centers), Germany (11 centers) and the
UK (14 centers), providing a range of geographic locations and in-
stitution types within each country. Medical records in each center
were screened for patients presenting with (or progressing to) stage IB-
IIIA NSCLC between 1 August 2009 and 31 July 2012. Each center
aimed to enroll between 5 and 30 patients. A limit of 30 patients per
center was imposed in order to avoid potential bias arising from dif-
ferences among centers in treatment practices combined with an im-
balance in the number of patients included from each center. In sites
with more than 30 potentially eligible patients, a systematic quasi-
random sampling method (i.e. based on a generated random number)
was used for patient selection to minimize the potential for selection
bias and domination of one site over the others.
2.1. Inclusion and exclusion criteria
Patients (living or deceased) identiﬁed by medical record screening
were eligible if they were ≥18 years of age, had undergone complete
resection (no residual disease) of stage IB-IIIA NSCLC, and if the in-
vestigator/study site had been the main care provider for the patient
during the period of NSCLC treatment or management.
Patients were excluded if they had undergone wedge resection, if
their resection was less than 1 month before study screening, if they had
received investigational adjuvant systemic treatment within a clinical
trial, if they had received treatment for concomitant cancer, or if they
were lost to follow-up. Patients who participated in randomized trials of
treatment after recurrence of NSCLC were included.
2.2. Study objectives and procedures
The objectives of the cost analysis were to estimate the level of
resource utilization, direct and indirect costs associated with managing
patients with resected stage IB-IIIA NSCLC during adjuvant treatment,
prior to disease recurrence/progression, and after disease recurrence/
progression. The study was designed to collect three types of resources
(direct costs, indirect costs, and patient out-of-pocket expenses) in order
to provide a real-world cost representation of NSCLC management. The
cost analysis included surviving patients in order to collect information
via a patient survey about healthcare resources from providers other
than their main NSCLC treatment center (for example local hospital
emergency care and general practitioner visits), indirect costs (lost
productivity for patients and caregivers), patient out-of-pocket ex-
penses (non-reimbursed transportation and childcare) and health-re-
lated quality of life (QoL) using the EQ-5D questionnaire. The study also
included patients who were deceased in order to research the period of
care up until the time of death.
Detailed information about demographic and disease character-
istics, disease progression, adjuvant treatment, and resource utilization
was extracted from patients’ medical records by their physicians or site
staﬀ using a custom electronic data collection form. Information was
collected from diagnosis until death, or until the last entry in the record.
The patient survey was administered to patients still living at the time
of the study. Patient surveys were completed from July 2013 through
January 2014. The recall period of the patient survey was limited to 3
months to minimize recall bias, but included exceptional events such as
hospitalizations and changes in employment status due to their NSCLC,
which the patient would be expected to recall with more reliability and
which represent substantial costs. Physicians did not send the survey to
patients if they felt that this was inappropriate for that patient.
Informed consent was collected only from living patients who
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participated in the patient survey according to country-speciﬁc proce-
dures.
2.3. Analysis
Descriptive summaries of results were generated by country and no
statistical comparisons were performed. Costs were estimated from the
healthcare provider and societal perspectives in euros (€) (and pounds
sterling, £, for the UK). Monetary values for resource use were identi-
ﬁed from published country-speciﬁc recognized sources (reference year
2013/inﬂation-adjusted to 2013). UK-speciﬁc costs were converted to
euros using an exchange rate of £1= €1.22 (2013).
Costs were summarized for each country for four disease phases: 1)
the adjuvant treatment period deﬁned as the period from the date of
surgical resection until the date adjuvant treatment ended; 2) the dis-
ease-free post-adjuvant (or no adjuvant) period, deﬁned as the period
from the date of surgical resection until the date of ﬁrst disease pro-
gression (death or end of follow-up, whichever came ﬁrst) in patients
who did not receive adjuvant treatment, and as the period from the date
adjuvant treatment ended until the date of ﬁrst disease progression
(death or end of follow-up, whichever came ﬁrst) in patients who had
received adjuvant treatment; 3) the period of locoregional recurrence
deﬁned as the period from the date of ﬁrst disease progression until the
date of detection of metastatic disease (death or end of follow-up,
whichever came ﬁrst) and; 4) distant metastatic and terminal disease,
deﬁned as the period from date of ﬁrst distant metastasis until the date
of death (or end of follow-up) in patients who did not experience a time
of locoregional recurrence only, and the period from the date of de-
tection of metastatic disease until the date of death (or end of follow-
up) in patients who did experience locoregional recurrence adjuvant
treatment period.
The duration of follow-up was the date of diagnosis until the end of
data collection or date of death. Resource utilization recorded in the
medical record abstraction form was analyzed over the duration of
follow-up. Resource utilization recorded in the patient survey for the
past 3 months was also reported. The following were estimated sepa-
rately for each of the disease phases and overall across all disease
phases:
• NSCLC-direct costs - treatments, adverse events, hospital and
emergency visits, diagnostics, hospice and other costs, and re-
imbursed transportation.
• Additional community care direct costs - medical care visits outside
of the participating physician’s oﬃce, and hospitalizations in a
hospital other than the NSCLC center.
• Indirect costs - cost of lost work days for patients or caregivers, and
costs associated with a change in job status due to NSCLC.
• Out-of-pocket expenses - cost of childcare, and non-reimbursed
transportation costs incurred by the patient or their family/friends.
For each patient, monthly costs were estimated by dividing his/her
total NSCLC-care costs accumulated during the disease phase by the
duration of follow-up (or recall) within the disease phase. Missing va-
lues were assumed to be the mean of the non-missing cost data within
each disease phase period. Analyses were performed using the software
SAS.
2.4. Estimation of direct costs from resource utilization data
Information on physician visits, hospitalizations, adjuvant treat-
ments, radiotherapy, post-progression systemic therapy, toxicity man-
agement, emergency room visits, rehabilitation, diagnostics, hospice
care and reimbursed transportation costs was collected from the med-
ical records. Not all patients included in the medical record abstraction
completed the patient survey, therefore the calculation of total direct
costs was made separately for data collected from medical record
abstraction (NSCLC direct costs) and from the patient survey (com-
munity care direct costs).
2.5. Estimation of lost productivity costs
The cost of lost work days for patients until death or the end of
follow-up (whichever came ﬁrst) and caregivers in work was estimated
from the number of work days lost that were reported in the patient
survey and the national average salary (from national statistics). The
cost associated with changes in job status (e.g. permanently disabled,
early retirement) due to NSCLC was estimated using the friction cost
method [11].
Because disability beneﬁts were obtained only from living patients
who completed the survey and not from all patients for whom a medical
record abstraction form was completed, they were not included in the
total direct costs but were reported separately to avoid bias due to
missing data. Disability beneﬁts were excluded from total indirect cost
estimates in the UK on the basis that these were transfer payments. For
France, disability beneﬁts are paid by the health insurance company
and were therefore included in the total direct costs (health insurance
perspective). For Germany, disability beneﬁts are not paid for the ﬁrst 6
weeks. Costs thereafter were included in the total direct costs (health
insurance perspective).
2.6. Estimation of out-of-pocket expenses
Out-of-pocket expenses were estimated based on the patient survey
3-month recall period. Childcare costs were estimated from the number
of days of childcare due to NSCLC and the unit daily cost for childcare
in each country. Transportation costs were estimated using the number
of visits to the main NSCLC treatment center from the medical record
abstraction, the usual method of transportation and journey time col-
lected in the patient survey, and cost estimates for each transportation
method. When available, journey costs used national data (e.g., statu-
tory mileage Approved Mileage Allowance Payments rates) or local data
examples (e.g., local taxi and public transport rates).
2.7. Estimation of national cost-of-illness
The national cost-of-illness due to Stage IB-/IIIA NSCLC (direct
costs, indirect costs, and out-of-pocket expenses) was computed based
on mean annual per-patient costs (12 × mean monthly costs) from the
current study multiplied by the number of prevalent cases of resected
Stage IB-/IIIA NSCLC in each country.
The annual incidence of all lung cancers in the study countries was
obtained from the 2012 EUCAN (European Cancer Observatory) reg-
istry [12]. Of all incident lung cancers, 85% were estimated to be
NSCLC [13–15]. 39% of incident NSCLC were estimated to present as
stages IB-IIIA, and 67% of these were estimated to undergo complete
surgical resection [16,17]. Annual incidence counts of resected Stage
IB-IIIA NSCLC were calculated as the product of these terms (annual
incidence count for all lung cancers in a given country× 0.85
×0.37× 0.67).
Prevalence counts in each country were estimated as the annual in-
cidence count multiplied by the average survival time (approximately 4
years) for patients with resected Stage IB-IIIA NSCLC based on data re-
ported by the International Adjuvant Lung Cancer Trial Collaborative
Group [18]. Annual per-person costs were obtained by multiplying
average monthly costs by 12, and national total costs were calculated by
multiplying annual per-person costs by the estimated prevalence counts.
3. Results
Data were extracted for 831 patients from 39 centers (Fig. 1). Of
these patients, 526 were invited to participate in the patient survey of
which 306 were completed (104 in France, 127 in Germany and 75 in
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the UK), with an overall response rate of 58% (306/526). The median
follow-up period for all patients was 26 months; 30 months in France,
24 months in Germany and 25 months in the UK.
Of 831 patients, 62% (513/831) were male, although the proportion
ranged from 70.9% in France to 61.0% in Germany and 54.6% in the
UK. Overall, 67% (557/831) were aged>65 years at diagnosis and
there were 20–30% of patients in each disease stage. Adenocarcinomas
were the most prevalent (53%) followed by squamous cell carcinoma
(38%), large cell tumors (2%) and other/unspeciﬁed (6%). Overall,
7.7% of patients had participated in clinical trials of post-recurrence
treatment. Clinical and disease characteristics and clinical outcomes of
patients are described in Chouaid et al. (back-to-back publication in this
journal issue).
3.1. Quality of life
The mean (95% conﬁdence interval [CI]) health utility weight es-
timates based on the EQ-5D index for the subset of patients providing a
patient survey were 0.72 (0.68–0.75) for patients who were disease-free
(n= 238, ranging from 0.71 in Germany to 0.73 in France), 0.62
(0.51–0.74) for patients with locoregional recurrence (n=19, ranging
from 0.58 in Germany to 0.66 in France) and 0.67 (0.55–0.78) for pa-
tients with distant metastasis and/or terminal disease (n= 32 ranging
from 0.59 in the UK to 0.73 in France and Germany). A higher EQ-5D
score indicates better QoL.
3.2. Direct costs
50% of patients were hospitalized during the adjuvant treatment
period for reasons other than adjuvant treatment administration, and
19% were hospitalized for events related to adjuvant therapy (Fig. 2).
The percentage of patients who were hospitalized, and the duration of
hospitalization, was the highest in distant metastatic and terminal
disease phase in all countries (Fig. 2). Overall resource consumption, in
terms of the number of episodes of use of each resource was the highest
Fig. 1. Patient disposition.
NSCLC: non-small cell lung cancer, UK: United Kingdom.
*12 patients had a progression date that was before/during adjuvant treatment
which continued unchanged after disease progression, 2 had a surgical resec-
tion date during/after adjuvant treatment, 4 reported a start of adjuvant
treatment date that was>100 days post surgery.
Fig. 2. Percentage of patients hospitalized by disease phase (from medical record abstraction).
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during the disease-free, distant metastatic and terminal disease phases
(Table 1).
Resource use was similar between countries except for generally
higher use of diagnostic tests in France and Germany than the UK;
higher use of radiotherapy in France during all disease stages; greater
use of chemotherapy during disease progression in France (see com-
panion publication) and longer duration of hospitalization in France
compared to Germany and the UK during disease progression
(Appendix A Tables A1 and A2). For example, during the period of
locoregional progression, the mean number of radiotherapy courses was
25.1 in France versus 3.5 in Germany and 1.2 in the UK; 65.8% of
patients received systemic chemotherapy in France compared to 42.3%
in Germany and 31.8% in the UK (see companion publication); and the
overall length of hospital inpatient stay was 19.3 days in France, 14.7
days in Germany and 14.0 days in the UK. Similar trends were observed
during the phase of distant metastatic and terminal disease (Appendix A
Table A2).
Additional resource consumption was also identiﬁed by the patient
survey including visits to or by healthcare professionals such as nurses
and general practitioners, visits to emergency departments, counseling
and periods spent in hospice or nursing home care (Appendix A Table
A3). Overall, 23.9% (74/306) of patients reported being hospitalized
outside of their main treatment center, with a mean length of stay of
13.9 days. Hospice stays were recorded by 17.3% of patients in France
(18/104), with a mean length of stay of 28.9 days.
The mean total direct cost per patient over the entire medical-record
follow-up period was €19,057 (95% Conﬁdence Interval [CI:]
16,770–21,429) in France, €14,185 (95% CI: 12,544–15,876) in
Germany, and €8377 (95% CI: 7310–9518) (£6,866, 95% CI:
5992–7802) in the UK (Fig. 3). The largest cost drivers were treatment
costs in France and, to a lesser extent, in the UK (€12,375 and 3694,
respectively), and hospitalization and emergency department costs in
Germany (€7706). The total mean per-patient costs associated with
management of adverse events during adjuvant treatment were €1063
in France, €1282 in Germany, and €894 (£733) in the UK.
In France and Germany, monthly direct costs per patient (the total
Table 1
Adjuvant treatment and resource use associated with resected Stage IB-IIIA NSCLC by disease phase for the major direct resource categories (from medical record
abstraction).
Variable Disease Phase
Adjuvant Treatment N=402 Disease-free post-
adjuvant N=402
Disease-free no
adjuvant N=204
Locoregional
recurrence
N=86
Distant metastatic
and terminal disease
N=200
Patients that received adjuvant treatment (N=831)
None N=429 (51.6%)
Cisplatin/vinorelbine N=258 (SD 64.2%), mean duration (wks) 9.4/10.3, planned
cumulative dose 323.2mg/m2 (SD 134.3)/173.2mg/m2 (SD 139.8)
Carboplatin/vinorelbine N=39 (9.7%), mean duration (wks) 9.0/9.3, planned
cumulative dose 19.2 mg/m2 (SD 4.1)/297.1 mg/m2 (SD 258.3)
Cisplatin/gemcitabine N=19 (4.7%), mean duration (wks) 8.0/ 9.1, planned cumulative
dose 273.5mg/m2 (SD 68.9)/4595.0mg/m2 (SD 1384.9)
Othera N=86 (10.3%)
Resource use Related to adjuvant treatment, mean number of
episodes (SD)
Unrelated to treatment, mean number of
episodes (SD)
Mean number of episodes (SD)
Oncologist visits 2.3 (2.0) 4.9 (3.9) 5.3 (4.1)
Surgeon visits 1.0 (-) 1.3 (0.9) 2.6 (2.2)
Pulmonologist/respiratory physician 1.4 (0.8) 5.1 (4.1) 4.6 (3.5)
Palliative care physician (G & UK) 0 8.0 (-) 0
Other specialist visits 1.1 (0.4) 1.6 (3.2) 3.2 (3.3)
Nurse visits (UK) 1.8 (1.5) 2.7 (1.6) 1.6 (0.8)
Hospitalizations 1.5 (1.0) 2.5 (2.1) 1.8 (1.4)
Duration of hospitalization (days) 7.3 (7.1) 10.0 (10.4) 12.3 (15.2)
Patient hotel/hospice stays (UK) 2.0 (1.0) 4.0 (3.0) –
Home hospital visits (G & F) – – –
ED visits 1.2 (0.5) 1.4 (0.8) 1.2 (0.6)
CT scans 1.1 (0.3) 1.6 (1.2) 3.5 (2.3)
MRI 1.0 (0.0) 1.1 (0.3) 1.4 (1.1)
PET scans 0 1.3 (0.5) 1.2 (0.4)
PET-CT combination 0 1.1 (0.3) 2.4 (2.2)
Ultrasound 1.0 (0.0) 1.3 (0.7) 2.5 (2.4)
Gamma-knife procedure 0 0 1.0 (-)
Nuclear medicine scans – – 1.4 (0.8)
Counseling sessions 1.7 (1.2) 1.4 (0.8) –
Ambulance transports 1.6 (0.9) 1.8 (1.3) 1.7 (1.8)
Other paid transport services 2.0 (1.4) 6.9 (6.9) 6.9 (8.0)
Radiotherapy courses – 11.0 (17.1) 9.8 (12.1)
Radiotherapy fractions – 39.8 (14.6) 44.2 (15.6)
Brachytherapy – – –
Laser surgery – – –
Photodynamic therapy – – –
NSCLC: non-small cell lung cancer, N: number of patients, SD: standard deviation, ED: emergency department, PET: positron emission tomography, CT: computer
tomography, MRI: magnetic resonance imaging, wks: weeks, UK: United Kingdom, G: Germany only, F: France only, UK: UK only.
a Includes: Carboplatin, Cisplatin, Docetaxel, Gemcitabine, Paclitaxel, Pemetrexed, Carboplatin+ either Etoposide, Gemcitabine, Paclitaxel, Pemetrexed or Other,
Cisplatin+ either Docetaxel, Etoposide, Paclitaxel, Pemetrexed, Vinblastine, or Other, Gemcitabine+Vinorelbine, Carboplatin+Docetaxel+Vinorelbine,
Carboplatin+ Etoposide+Other, Carboplatin+Paclitaxel+Vinorelbine, Cisplatin+Etoposide+Gemcitabine, Cisplatin+Gemcitabine+Vinorelbine,
Cisplatin+ Paclitaxel+Vinorelbine.
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direct costs divided by the number of months the patient spent in the
diﬀerent disease phases) were the highest during the distant metastasis/
terminal illness phase (€15,562 based on 76 patients in France and
€6047 based on 66 patients in Germany), followed by the adjuvant
treatment period (€2361 based on 155 patients in France and €2278
based on 149 patients in Germany) (Table 2). In the UK, the largest
monthly direct costs per patient were for the adjuvant treatment period
(€2490 based on 98 patients) followed by the distant metastasis or
terminal illness phase (€2162 based on 58 patients).
3.3. Indirect costs and out-of-pocket expenses
One half (51.5%, 428/831) of patients were of working age
(aged<65 years) at diagnosis and, approximately 10% of patients
overall (30/302, data missing for 4 patients) reported being on long-
term (>3 months) sick leave, disability leave, permanently disabled or
a leave of absence from their job. Overall, 24.7% (70/283, data was
missing for 23 patients) stated that their employment status changed as
a result of their lung cancer; 16% of patients (15/97, 7 with missing
data) in France, 36% (44/122, 5 with missing data) in Germany, and
17% (11/64, 11 with missing data) in the UK. Of 50/302 patients
(16.6%) across all countries who were employed full-time or part-time
at the time of the survey, 19 (38%) reported missing a median of 2
weeks of work (mean 32.0 days) in the last 3 months.
Overall, 8% (25/306) of patients received disability beneﬁts for a
mean of 17 weeks. To provide a cost estimate for the disability beneﬁts,
the duration of beneﬁts was combined with country-speciﬁc unit costs.
In the UK, the overall cost was €105 (£86) per patient; however, due to
the method by which disability costs are paid in France and Germany,
disability costs were bundled with additional community-care direct
costs in these countries. Total community-care direct costs were €3423
per patient in France, €1265 per patient in Germany, and €794 (£651)
per patient in the UK. Mean total indirect costs per patient were esti-
mated as €696 for France, €2476 for Germany, and €1414 (£1159) for
the UK (Table 2).
3.4. National cost-of-illness
The annual incidence estimate for completely resected stage IB-IIIA
NSCLC was 8895 in France, 11,287 in Germany, and 8970 in the UK
(Table 3). The corresponding national prevalence count estimates were
35,580 in France, 45,148 in Germany, and 35,880 in the UK. The ﬁnal
prevalence estimates, when combined with the annual per-person costs
for direct, indirect and patient out-of-pocket expenses, provided annual
cost estimates for stage IB-IIIA NSCLC of approximately €478.4 million
in France, €574.6 million in Germany and €325.8 million (£267.1
million) in the UK (Table 3). The annual indirect national cost estimates
were approximately €35.7 million in France, €111.5 million in
Fig. 3. Direct costs (per patient) associated with NSCLC over the follow-up period by country for the major direct resource category (medical record abstraction).
Country (n= x), y=number of patients and mean duration of follow-up for the speciﬁed phase and country.
Treatment costs= systemic therapy, radiotherapy, gamma knife procedures, brachytherapy, laser surgery, photodynamic therapy, and embolization, and are ob-
tained by adding up the treatments during the adjuvant treatment period during the no-recurrence period and systemic therapy and chemotherapy received during
later phases along with the associated administration costs.
Supportive treatment costs= Supportive treatment during the adjuvant treatment period including pegﬁlgrastim, ﬁlgrastim, erythropoietin, and aprepitant.
Visit costs=Visits to specialists (oncologist, pulmonologist/respiratory specialist, palliative care physician, surgeon, other), nurse visits, and counseling.
Diagnostic costs= X-rays, PET, CT, PET-CT scans, MRI, nuclear.
Hospice and other care costs = Home/hospital medical care in the home.
Reimbursed transport costs=Ambulance and other transportation to the primary NSCLC-care clinic, or other transports paid by health services.
NSCLC: non-small cell lung cancer, n: number of patients, UK: United Kingdom, MRI: magnetic resonance imaging, PET: positron emission tomography, CT: CT:
computed tomography.
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Germany, and €79.4 (£65.1) million in the UK. Annual out-of-pocket
expense estimates were reported for Germany (approximately €3.4
million for non-reimbursed transportation) and the UK (€2.9 million
[£2.4] for non-reimbursed transportation and €1.08 million [£887,649]
for childcare) only. In France, annual out-of-pocket expense estimates
were assumed to be zero where cancer care (including medical trans-
portation) was fully covered by the national health insurance under the
status of long-term illness.
4. Discussion
To our knowledge, this is the ﬁrst study to comprehensively de-
scribe the burden of illness in patients with completely resected stage
IB-IIIA NSCLC. This study assessed healthcare utilization and costs
among patients with resected stage IB-IIIA NSCLC diagnosed in France,
Germany and the UK between 2009 and 2012. A combination of
medical-record data abstraction and a patient survey allowed us to
capture information about resource use from a wide range of service
providers, and to estimate the ﬁnancial burden for patients, caregivers
and their employers. Uniquely, our study estimated the cost of adverse
events associated with adjuvant treatment, as well as indirect costs that
are often absent in many cost-of-illness studies.
In each country, the monthly mean per-patient direct costs were higher
after disease recurrence (locoregional or distant metastasis/terminal disease
phases) than during the disease-free period. Costs during the adjuvant
treatment phase were also substantial, driven largely by the costs of drugs
and hospitalizations/emergency department visits.
The overall costs of treating resected Stage IB-IIIA NSCLC, and the
monthly distribution of costs over each disease phase varied considerably in
each country. These contrasts reﬂect diﬀerences in patterns of resource
consumption in each country, with less use of radiotherapy or che-
motherapy after disease progression, as well as fewer investigations and
shorter hospitalizations in the UK, compared, in particular, with France.
Some of this variability will also reﬂect diﬀering unit costs, diﬀering dis-
tribution of direct/indirect/out-of-pocket expenses in each country and
diﬀerent coverage of some expenses by the local healthcare system. For
example, out-of-pocket expenses to the patient in France are low due to the
high coverage of these costs by the national health insurance.
Table 2
Costs per patient (mean, 95% CI) and monthly costs associated with NSCLC for the overall follow-up period, by country and disease phase.
Variable Data source Disease Phase Overall
Adjuvant
treatmenta
Disease-free
(post/no adjuvant)
Locoregional
recurrence
Distant metastatic
and terminal disease
Per-patient costs (mean, 95% CI)
France, €
Direct costs Medical records 9151 (7991–10,446) 4199 (3321–5146) 20,475 (15,698–25,565) 20,280 (16,550–24,362) 19,057 (16,770–21,429)
Out-of-pocket expenses Medical records 0 0 0 0 0
Community care direct costs Patient survey 1702 (867–2696) 2331 (1417–3382) 48 (0–112) 547 (168–990) 3423 (2,367–4,608)
Indirect costs Patient survey 184 (0–475) 522 (207–905) 109 (0–339) 336 (0–1120) 696 (292–1172)
Germany, €
Direct costs Medical records 8955 (7728–10,287) 3930 (3379–4512) 12,638 (8979–16,461) 19,460 (15,581–23,700) 14,185 (12,544–15,876)
Out-of-pocket expenses Medical records 55 (44–68) 59 (50–70) 56 (31–94) 146 (75–249) 126 (100–158)
Community care direct costs Patient survey 589 (189–1068) 521 (312–776) 1632 (49–5145) 1876 (381–4006) 1265 (772–1842)
Indirect costs Patient survey 1106 (473–1835) 1718 (1067–2423) 0 554 (0–1813) 2476 (1716–3289)
UK, €
Direct costs Medical records 9032 (7692–10,777) 2815 (2,416-3,262) 7565 (5115–10,286) 9969 (7952–12,048) 8377 (7310–9518)
Out-of-pocket expenses Medical records 95 (87–104) 74 (66–84) 112 (74–154) 87 (67–107) 132 (120–145)
Community care direct costs Patient survey 162 (0–425) 565 (271–909) 506 (0–2028) 2197 (0–4231) 794 (415–1231)
Indirect costs Patient survey 1249 (281–2500) 755 (203–1476) 0 3395 (0–10,951) 1414 (620–2336)
Per-patient monthly costs (mean, 95% CI)
France, €
Direct costs Medical records 2361 (2065–2706) 342 (252–445) 1846 (1326–2433) 15,562 (2453–41,277) 780 (679–888)
Out-of-pocket expenses Medical records 0 0 0 0 0
Community care direct costs Patient survey 413 (216–645) 214 (93–381) 16 (0–37) 145 (31–278) 257 (133–426)
Indirect costs Patient survey 25 (0–76) 77 (9–173) 36 (0–113) 20 (0–61) 84 (14–183)
Germany, €
Direct costs Medical records 2278 (2006–2563) 408 (317–511) 1542 (1056–2086) 6047 (2259–11,669) 757 (648–870)
Out-of-pocket expenses Medical records 15 (12–18) 5 (4-6) 6 (4–10) 28 (14–45) 6 (5–8)
Community care direct costs Patient survey 192 (55–362) 56 (37–79) 93 (16–237) 168 (74–280) 92 (64–123)
Indirect costs Patient survey 366 (130–665) 178 (89–287) 0 40 (0–118) 206 (116–316)
UK, €
Direct costs Medical records 2490 (2163–2863) 368 (245–519) 847 (655–1032) 2162 (1631–2757) 492 (405–587)
Out-of-pocket expenses Medical records 27 (24–29) 6 (5–7) 12 (9–15) 15 (11–17) 7 (6–7)
Community care direct costs Patient survey 49 (0–132) 46 (24–79) 48 (0–190) 750 (0–1459) 71 (35–120)
Indirect costs Patient survey 372 (81–749) 94 (18–220) 0 1132 (0–3650) 184 (40–389)
NSCLC: non-small cell lung cancer, CI: conﬁdence interval (95 percentile bootstrapped CI using 10,000 samples), SD: standard deviation, UK: United Kingdom.
aCosts in the adjuvant treatment phase are the mean among patients who received adjuvant treatment, not the mean among all patients in the cohort (some patients
did not receive adjuvant treatment).
Total NSCLC-care direct costs include treatment costs, supportive treatment costs, hospitalizations and emergency costs, visit costs, diagnostic costs, hospice and
other care costs, and reimbursed transportation costs (medical record abstraction).
Missing costs are imputed from patients with available data.
Total out-of-pocket expenses are determined by adding up the non-reimbursed transportation costs associated with treatment visits and visits to specialists (medical
record abstraction).
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Costs for patients receiving adjuvant treatment were similar across
all three countries (range €8955–€9151 during the treatment period).
However, total overall direct costs were lower in the UK (€8377)
compared to France and Germany (€19,057 and €14,185 respectively).
This was largely due to a lower proportion of patients receiving ad-
juvant therapy (33.4% in the UK versus 61.8% in France and 51.9% in
Germany) and lower costs after disease progression in the UK.
While we did not identify any study describing the overall costs of
care associated with resected NSCLC, there are published data that
describe the cost of care of advanced (Stage IIIB and IV) NSCLC. The
total per-patient cost of care of advanced (Stage IIIB and IV) NSCLC in
Spain was estimated between €11,301 and €32,754 (from the start of
active anti-cancer therapies until death), varying according to the
number of treatments received (2009 prices) [19]. In the United States,
the cost of treating advanced NSCLC increased substantially during
disease progression, and the authors concluded that disease progression
was a signiﬁcant clinical event in terms of cost implications [20]. One
Mexican study that included all lung cancer types and early disease
stages, estimated that the annual cost per patient of Stage I disease was
$13,456, Stage II disease $35,648 and Stage III disease $106,186 (2013
prices) [21]. Chemotherapy treatments exceeded other costs during
Stages II and III. None of these studies considered the contribution of
indirect costs and costs of adverse events to the overall burden of ill-
ness, and several used modeling approaches based on expert panels and
published data to determine time to disease progression.
We collected real-world information from a large cohort of patients
with NSCLC. This approach provides advantages to previous studies
because it provides a comprehensive view of the resource use and
clinical outcomes of patients with NSCLC. Our wide-range approach
collected information about diagnostic tests performed, visits and
treatment by nurses and home hospital staﬀ, and information on the
direct costs of community care via the patient survey. Furthermore, we
collected data using a combination of practicing-physician-led char-
acterization of medical practice through medical record review, and
patient-reported data collected via a patient survey. This combination
of data sources allowed for timely collection of a wide range of direct
and indirect costs, including costs accrued outside of the main NSCLC
center of care, and is therefore more likely to represent the true eco-
nomic burden of illness incurred by the participating patients. The
patient survey was able to collect data from local hospital care or
emergency department visits, but these data may not have been fully
captured since we relied on patient recall and a limited recall period of
3 months. Recall bias and uncertainty around the accuracy of the in-
formation collected through the patient survey is a potential limitation
of our study.
QoL measures suggested a higher utility score during the period of
distant metastasis and/or terminal disease than in the period of locor-
egional recurrence. However, there were few patients who provided
QoL data during these stages, resulting in wide 95% CIs.
While we selected sites to achieve variation in geographic location,
size, and type of center, the study data are not guaranteed to be re-
presentative of all sites and physicians treating patients with stage IB-
IIIA NSCLC across each country, potentially leading to inaccuracies in
our national cost-of-illness estimates. Furthermore the limited sample
size may also be a source of imprecision. No external validation of data
from the medical record abstractions was possible because of the need
to protect patient conﬁdentiality. As is the case with all studies that rely
on existing medical records, availability of information in records
varied by physician practice and by country, and reﬂects diﬀerences in
practice patterns, recording practices, and medical norms.
Table 3
National total cost-of-illness estimates.
Variable France Germany UK
Epidemiological data N N N
Annual incident casesa 13,275 16,845 13,387
Complete surgical resection n (%)b 8895 11,287 8970
Estimated prevalence counts of cases with complete surgical resectionc 35,580 45,148 35,880
Cost € € €
Annual costs per persond
Direct costs (medical record abstraction) 9356 9082 5902
Additional community care costs (patient survey) 3085 1099 855
Indirect costs (patient survey) 1,004 2,470 2,212
Out-of-pocket expenses per person
Non-reimbursable travel (medical record abstraction) N/A 75 81
Childcare (patient survey) 0 0 29
Annual national costse
Direct costs (medical record abstraction) 332,891,172 410,025,654 211,780,864
Additional community care costs (patient survey) 109,748,612 49,624,540 30,694,718
Indirect costs (patient survey) 35,732,330 111,528,429 79,385,280
Non-reimbursable travel (medical record abstraction) N/A 3,396,523 2,897,169
Childcare (patient survey) 0 0 1,082,932
NSCLC: non-small cell lung cancer, N: number of patients, N/A: not applicable, UK: United Kingdom.
a Country-speciﬁc incidences in 2012 were obtained from the European Cancer Observatory (EUCAN) [11]. 85% of incidence cancers were estimated
to be NSCLC [12–14].
b Among patients with stage IB-IIIA NSCLC, 39% of incident NSCLC were estimated to present as stages IB-IIIA, and 67% of these were estimated to
undergo complete surgical resection [15,16]. The annual incidence counts of patients with newly diagnosed stage IB-IIIA NSCLC with complete surgical
resection was obtained by multiplying counts in row 1 by 0.67. Values were rounded to the next higher integer.
c Prevalence counts were obtained by multiplying incidence counts in row 2 by the median survival time of patients with stage IB-IIIA NSCLC and
complete surgical resection, taken as 4 years from [17]. Values were rounded to the next higher integer.
d Per-person-costs were obtained by multiplying the average monthly costs by 12.
e National total costs were obtained by multiplying the per-person costs by the estimated prevalence of counts of stage IB-IIIA NSCLC patients with
complete surgical resection.
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5. Conclusions
Our study provides real-world data describing country-speciﬁc costs
associated with the treatment of Stage IB-IIIA NSCLC. Treatment of
Stage IB-IIIA NSCLC is associated with large annual national costs in all
three countries of which a majority is incurred during disease pro-
gression. The study ﬁndings can assist decision-makers to understand
cost patterns associated with the management of NSCLC, and can be
used for assessing the beneﬁts and costs of new NSCLC treatments.
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Appendix A
Table A1
Resource use associated with resected Stage IB-IIIA NSCLC during the adjuvant treatment period and disease-free periods, by country, for the major
direct resource categories (from medical record abstraction).
France Germany UK
Adjuvant treatment period: unrelated to adjuvant
treatment, mean number of episodes (SD)
N=155 N=149 N=98
Oncologist visits 2.8 (2.9) 6.9 (4.9) 4.5 (2.0)
Surgeon visits 1.3 (0.9) 1.3 (0.5) 1.5 (0.9)
Pulmonologist/respiratory physician 5.5 (4.3) 6.0 (3.4) 1.4 (0.7)
Other specialist visits 1.4 (0.9) 2.8 (6.7) 1.1 (0.3)
Hospitalizations 2.5 (1.5) 3.0 (2.8) 1.7 (1.0)
Duration of hospitalization (number of days) 8.4 (11.0) 13.3 (10.9) 6.3 (4.4)
ED visits 1.5 (1.0) 1.3 (0.6) 1.1 (0.4)
CT scans 1.8 (1.6) 1.5 (0.9) 1.6 (1.0)
MRI 1.0 (0) 1.2 (0.4) 0
PET scans 1.4 (0.6) 1.3 (0.5) 1.0 (-)
Ultrasound 1.8 (0.8) 1.3 (0.6) 1.1 (0.4)
Counseling sessions 1.4 (0.6) 1.4 (0.9) 1.0 (-)
Ambulance transports 1.7 (1.2) 1.4 (0.7) 3.3 (2.3)
Other paid transport services 7.9 (6.9) 4.8 (7.5) 2.0 (-)
Radiotherapy courses 23.8 (21.9) 1.8 (2.5) 7.3 (11.0)
Radiotherapy fractions 46.8 (12.7) 33.8 (11.4) 20.0 (0.0)
Adjuvant treatment period: related to treatment,
mean number of episodes (SD)
N=155 N=149 N=98
Oncologist visits 1.3 (0.8) 3.0 (2.3) 1.4 (0.9)
Pulmonologist/respiratory physician 1.5 (1.0) 1.2 (0.5) 1.0 (-)
Other specialist visits 1.2 (0.4) 1.0 (0.0) 0
Hospitalizations 1.3 (0.8) 1.9 (1.3) 1.3 (0.5)
Duration of hospitalization (number of days) 3.9 (3.5) 12.1 (9.2) 5.3 (3.5)
ED visits 1.1 (0.4) 1.3 (0.7) 1.0 (0.0)
Ambulance transports 3.0 (-) 1.3 (0.5) 0
Disease-free period post-adjuvant treatment,
mean number of episodes (SD)
N=155 N=149 N=98
Oncologist visits 4.8 (3.4) 6.7 (4.5) 4.1 (3.9)
Surgeon visits 1.9 (1.5) 2.5 (3.3) 3.1 (2.0)
Pulmonologist/respiratory physician 5.5 (3.8) 3.3 (2.5) 3.3 (2.3)
Other specialist visits 3.3 (3.7) 3.4 (2.9) 2.8 (2.6)
Hospitalizations 1.5 (0.9) 2.2 (1.7) 1.5 (0.8)
Duration of hospitalization (number of days) 10.3 (10.9) 13.1 (14.4) 13.9 (23.4)
ED visits 1.1 (0.4) 1.2 (0.8) 1.4 (0.7)
CT scans 3.8 (2.3) 3.9 (2.3) 2.0 (1.1)
MRI 1.2 (0.4) 1.7 (1.4) 1.0 (0.0)
PET scans 1.2 (0.5) 1.2 (0.4) 1.0 (0.0)
Ultrasound 1.2 (0.4) 3.0 (2.7) 1.8 (1.2)
Nuclear medicine studies 1.2 (0.4) 1.6 (1.0) 1.3 (0.5)
Ambulance transports 3.3 (3.2) 1.0 (0.0) 1.3 (0.5)
Radiotherapy courses 22.8 (9.5) 1.6 (1.6) 1.0 (0.0)
Radiotherapy fractions 54.3 (12.6) 30.5 (7.6) 55.0 (0.0)
Disease-free period no adjuvant treatment, mean
number of episodes (SD)
N=96 N=138 N=195
Oncologist visits 5.2 (2.8) 6.2 (5.4) 2.9 (2.8)
Surgeon visits 1.6 (1.2) 2.9 (2.8) 4.1 (2.9)
Pulmonologist/respiratory physician 4.8 (3.9) 3.4 (2.9) 4.0 (3.3)
Other specialist visits 4.1 (4.5) 2.8 (2.2) 4.3 (5.0)
Hospitalizations 1.9 (1.7) 1.9 (1.4) 1.8 (1.3)
Duration of hospitalization (number of days) 24.5 (26.8) 21.5 (30.4) 11.2 (11.9)
ED visits 1.5 (0.6) 1.6 (0.8) 1.7 (1.0)
CT scans 3.7 (2.2) 3.6 (2.1) 1.8 (1.1)
MRI 1.1 (0.3) 1.7 (1.4) 1.1 (0.3)
PET scans 1.0 (0.0) 1.0 (-) 1.2 (0.6)
PET-CT scans 1.2 (0.6) 1.0 (0.0) 1.3 (0.6)
Ultrasound 1.5 (1.1) 3.6 (3.0) 1.5 (0.8)
Nuclear medicine studies 1.0 (0.0) 1.5 (1.0) 1.0 (0.0)
Radiotherapy courses 24.5 (6.8) 1.0 (0.0) 3.9 (7.1)
Radiotherapy fractions 49.4 (12.5) 28.4 (14.8) 25.9 (18.4)
NSCLC: non-small cell lung cancer, N: number of patients, SD: standard deviation, ED: emergency department, PET: positron emission tomography,
CT: computer tomography, MRI: magnetic resonance imaging, UK: United Kingdom, G: Germany only, F: France only, UK: UK only.
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country, for the major direct resource categories (from medical record abstraction).
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Table A3
Resource use associated with resected Stage IB-IIIA NSCLC in all patients from the patient survey.
Variable, mean number of episodes (SD) (past 3 months) Overall N= 306
General practitioner visits at home 2.1 (1.2)
General practitioner visits in the clinic 2.4 (2.2)
Hospital doctor/specialist visits outside of the main treatment center 1.7 (1.5)
Nurse visits at home 33.6 (31.3)
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Emergency department visits 1.4 (0.7)
Counseling or psychological support visits 3.1 (3.1)
Number of hospital inpatient stays 1.5 (0.9)
Duration of hospital stays (days) 13.9 (14.5)
Number of hospice/nursing home stays 1.1 (0.2)
Duration of hospice/nursing home stays 28.9 (19.0)
Days of missed work 32.0 (33.9)
Days of work missed by family member or unpaid caregiver 14.7 (26.6)
Weeks of disability beneﬁts 17.4 (22.0)
Days of childcare 5.0 (-)
N: number of patients, SD: standard deviation, NSCLC: non-small cell lung cancer.
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